

Managing GI Malignancies With Targeted Therapeutics

Focus on NET, GIST, and HCC


ESMO Vienna 2012 Industry Satellite Symposium

28 September 2012 • 16.30 – 18.30
Hall D • ACV—Austria Center Vienna



This symposium is intended for non-US physicians.

Novartis Pharma AG
CH-4002 Basel, Switzerland
G-AFI-1046043 © Novartis 2012 July 2012



Managing GI Malignancies With Targeted Therapeutics

Focus on NET, GIST, and HCC

28 September 2012 • 16.30 – 18.30

Overall Objectives

- Educate on current challenges in selecting the most appropriate therapy for patients with advanced neuroendocrine tumors (NET)
- Educate on current controversies regarding adjuvant therapy for patients with surgically resected gastrointestinal stromal tumors (GIST)
- Describe investigational targeted agents in development for advanced HCC
- Educate on the growing need for a personalized therapeutic approach to management of advanced gastrointestinal malignancies

16.30 - 17.00	Reception	
17.00 - 17.05	Introduction	Peter Reichardt Chair
17.05 - 17.15	Selecting the Best Treatment Strategy for Patients With Advanced NET	Marianne Pavel
17.15 - 17.35	Discussion of Two Cases: pNET and Carcinoid	Marianne Pavel
17.35 - 17.50	Clinical Practice Controversies Regarding Adjuvant Therapy for Surgically Resected GIST	Peter Reichardt
17.50 - 18.05	Discussion of Cases: Best Practices in the Use of Adjuvant Therapy for GIST	Peter Reichardt
18.05 - 18.25	The Evolving Therapeutic Landscape for Advanced HCC	Bruno Daniele
18.25 - 18.30	Summary and Future Directions	Peter Reichardt Chair